Berenberg raises target for Redcare Pharmacy stock from EUR 94.00 to EUR 102.00

Published on 10/08/2026 at 14:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare targets 16 to 18 percent growth for 2026, up from 15 to 17 percent. Redcare Pharmacy stock costs EUR 74.28 on October 8, 2026 versus EUR 75.15.

Architektur-Render eines modernen Pharma-Verteilzentrums mit Glasfassade in der Dämmerung — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, illustriert Architektur-Render eines Pharma-Verteilzentrums mit Glasfassade bei Dämmerung, Illustration mit AI erstellt.

Berenberg raised its Redcare Pharmacy target from EUR 94.00 to EUR 102.00 in a study published October 6, 2026, and retained its Buy rating, according to finanzen.ch. Redcare Pharmacy stock (ISIN NL0012044747) was EUR 74.28 at Lang & Schwarz at 2:17 p.m. CEST on October 8, 2026.

Three dated signals

On July 29, 2026, Redcare reported second-quarter revenue growth of 20 percent year over year and an adjusted EBITDA margin of 3.50 percent, according to the Yahoo Finance transcript. On September 28, 2026, Redcare Pharmacy lifted full-year 2026 group revenue growth guidance to 16 to 18 percent from 15 to 17 percent. On October 6, 2026, Berenberg lifted its target to EUR 102.00 from EUR 94.00 while keeping Buy, according to finanzen.ch.

What does the target increase mean for margins

The operating picture is improving, but the margin target remains a key test. Redcare confirmed an adjusted EBITDA margin range of 2.50 to 3.00 percent for full-year 2026, while the second-quarter margin reached 3.50 percent. That gap gives the company room to meet its lower-end profitability goal, but the full-year range remains below the latest quarterly level.

The revenue upgrade is concentrated in German prescription medicine. Redcare now expects full-year 2026 German Rx revenue of EUR 730 million to EUR 760 million, up from EUR 680 million to EUR 720 million previously, with projected growth of 45 to 51 percent versus 35 to 43 percent. The company said preliminary German Rx revenue rose 56 percent in the third quarter of 2026 and 51 percent in September.

Dates for the next test

Redcare Pharmacy will publish its third-quarter 2026 interim statement and hold its quarterly conference call on October 29, 2026. Its annual report for 2026 is scheduled for March 4, 2027, giving investors two dated milestones for checking whether prescription growth is translating into sustained profitability.

Stock remains below its yearly high

Redcare Pharmacy stock was EUR 74.28 at Lang & Schwarz on October 8, 2026 at 2:17 p.m. CEST, down 1.16 percent versus the Xetra close of EUR 75.15 on October 7, 2026. The primary-market 52-week range was EUR 30.20 to EUR 90.05 as of October 8, 2026, while market capitalization was EUR 1.5 billion. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.